Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2010 3
2011 1
2014 1
2015 1
2016 2
2017 3
2018 4
2019 4
2020 9
2021 5
2022 2
2023 4
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for peterschmitt mj
Search for Peterschmi MJ instead (1 results)
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Giladi N, Alcalay RN, Cutter G, Gasser T, Gurevich T, Höglinger GU, Marek K, Pacchetti C, Schapira AHV, Scherzer CR, Simuni T, Minini P, Sardi SP, Peterschmitt MJ. Giladi N, et al. Among authors: peterschmitt mj. Lancet Neurol. 2023 Aug;22(8):661-671. doi: 10.1016/S1474-4422(23)00205-3. Lancet Neurol. 2023. PMID: 37479372 Clinical Trial.
Accelerating Parkinson's Disease drug development with federated learning approaches.
Khanna A, Adams J, Antoniades C, Bloem BR, Carroll C, Cedarbaum J, Cosman J, Dexter DT, Dockendorf MF, Edgerton J, Gaetano L, Goikoetxea E, Hill D, Horak F, Izmailova ES, Kangarloo T, Katabi D, Kopil C, Lindemann M, Mammen J, Marek K, McFarthing K, Mirelman A, Muller M, Pagano G, Peterschmitt MJ, Ren J, Rochester L, Sardar S, Siderowf A, Simuni T, Stephenson D, Swanson-Fischer C, Wagner JA, Jones GB. Khanna A, et al. Among authors: peterschmitt mj. NPJ Parkinsons Dis. 2024 Nov 21;10(1):225. doi: 10.1038/s41531-024-00837-5. NPJ Parkinsons Dis. 2024. PMID: 39567515 Free PMC article. Review.
Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals.
Mistry PK, Cassiman D, Jones SA, Lachmann R, Lukina E, Prada CE, Wasserstein MP, Thurberg BL, Foster MC, Patel RM, Underhill LH, Peterschmitt MJ. Mistry PK, et al. Among authors: peterschmitt mj. Hepatol Commun. 2025 Jan 7;9(1):e0621. doi: 10.1097/HC9.0000000000000621. eCollection 2025 Jan 1. Hepatol Commun. 2025. PMID: 39774103 Free PMC article.
Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma.
Ramaswami U, Mengel E, Berrah A, AlSayed M, Broomfield A, Donald A, Seif El Dein HM, Freisens S, Hwu WL, Peterschmitt MJ, Yoo HW, Abdelwahab M. Ramaswami U, et al. Among authors: peterschmitt mj. Mol Genet Metab. 2021 Aug;133(4):335-344. doi: 10.1016/j.ymgme.2021.06.009. Epub 2021 Jun 25. Mol Genet Metab. 2021. PMID: 34229967 Free article. Review.
Utility of hemodialysis in maple syrup urine disease.
Puliyanda DP, Harmon WE, Peterschmitt MJ, Irons M, Somers MJ. Puliyanda DP, et al. Among authors: peterschmitt mj. Pediatr Nephrol. 2002 Apr;17(4):239-42. doi: 10.1007/s00467-001-0801-2. Pediatr Nephrol. 2002. PMID: 11956873 Review.
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.
Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillic S, Alcalay RN, Cutter G, Hattori N, Höglinger GU, Marek K, Schapira AHV, Scherzer CR, Simuni T, Giladi N, Sardi SP, Fischer TZ; MOVES-PD Investigators. Peterschmitt MJ, et al. J Parkinsons Dis. 2022;12(2):557-570. doi: 10.3233/JPD-212714. J Parkinsons Dis. 2022. PMID: 34897099 Free PMC article. Clinical Trial.
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, Cox GF, Danda S, Dragosky M, Drelichman G, El-Beshlawy A, Fraga C, Freisens S, Gaemers S, Hadjiev E, Kishnani PS, Lukina E, Maison-Blanche P, Martins AM, Pastores G, Petakov M, Peterschmitt MJ, Rosenbaum H, Rosenbloom B, Underhill LH, Cox TM. Mistry PK, et al. Among authors: peterschmitt mj. Blood Cells Mol Dis. 2018 Jul;71:71-74. doi: 10.1016/j.bcmd.2018.04.001. Epub 2018 Apr 9. Blood Cells Mol Dis. 2018. PMID: 29680197 Free article. No abstract available.
39 results